Background: Cancer-related pain is highly prevalent among outpatients with metastatic breast cancer affecting their health-related quality of life (HRQoL). This study evaluates potential effects of comprehensive pharmacologic cancer pain therapy (CPT) on HRQoL. Patients and Methods: 52 outpatients with metastatic breast cancer undergoing palliative chemotherapy participated. 28 patients suffering from moderate to severe cancer pain were offered CPT. 13 patients participated (intervention group), and 15 declined participation (control group). HRQoL was assessed with the Quality of Life Questionnaire (EORTC QLQ-C30) and the breast module QLQ-BR23 at baseline and after 3 weeks. Results: At baseline, 83% of the patients experienced cancer-related pain, of whom 35% were not prescribed any pain medication. HRQoL of all patients was reduced compared to reference scores. After CPT, the intervention group reported significantly alleviated pain and improvement in several HRQoL subscales (Global QoL, Emotional Functioning, Physical Functioning, Future Perspective, Sleeplessness). The control group did not change significantly. Conclusion: This study emphasizes the demand for sufficient pain management in palliative breast cancer outpatients. The combination of CPT as a guidance for the pharmacological aspects of cancer pain management and the EORTC QLQ-C30 as an assessment and surveillance tool appears to be a method that warrants further research.

Journal Section:
Original Article
Keywords:
Metastatic breast cancer, Cancer pain management, Comprehensive pain therapy, Health-related quality of life, HRQoL
1.
Ferlay JS, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Globocan 2008 v2.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, International Agency for Research on Cancer, 2010. globocan.iarc.fr, accessed on 28/6/2013.
2.
Boyle P, Levin B (eds): WHO World Cancer Report 2008. IARC Press, Lyon, 2008, p. 510.
3.
American Cancer Society: Breast Cancer Facts & Figures 2011-2012. Atlanta, GA, ACS, 2011.
4.
Miaskowski C, Dibble SL: The problem of pain in outpatients with breast cancer. Oncol Nurs Forum 1995;22:791-797.
[PubMed]
5.
Haegerstam GAG: Pathophysiology of bone pain: a review. Acta Orthop Scand 2001;72:308-317.
[PubMed]
https://doi.org/10.1080/00016470152846682
6.
Fairchild A: Under-treatment of cancer pain. Curr Opin Support Palliat Care 2010;4:11-15.
[PubMed]
https://doi.org/10.1097/SPC.0b013e328336289c
7.
Katz N: The impact of pain management on quality of life. J Pain Symptom Manage 2002;24:S38-47.
[PubMed]
https://doi.org/10.1016/S0885-3924(02)00411-6
8.
Gureje O, von Korff M, Simon GE, Gater R: Persistent pain and well-being: a world health organization study in primary care. JAMA 1998;280:147-151.
[PubMed]
https://doi.org/10.1001/jama.280.2.147
9.
Bjordal K: Impact of quality of life measurement in daily clinical practice. Ann Oncol 2004;15(suppl 4):iv279-282.
[PubMed]
https://doi.org/10.1093/annonc/mdh939
10.
Chen TH, Li L, Kochen MM: A systematic review: how to choose appropriate health-related quality of life (HRQoL) measures in routine general practice? J Zhejiang Univ Sci B 2005;6:936-940.
[PubMed]
https://doi.org/10.1631/jzus.2005.B0936
11.
Velikova G, Stark D, Selby P: Quality of life instruments in oncology. Eur J Cancer 1999;35:1571-1580.
[PubMed]
https://doi.org/10.1016/S0959-8049(99)00193-8
12.
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842.
[PubMed]
https://doi.org/10.1001/jama.280.21.1837
13.
Katz NP, Gammaitoni AR, Davis MW, Dworkin RH: Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med 2002;3:324-332.
[PubMed]
https://doi.org/10.1046/j.1526-4637.2002.02050.x
14.
Ehrich EW, Bolognese JA, Watson DJ, Kong SX: Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care 2001;7:609-616.
[PubMed]
15.
Vinik A, Emir B, Cheung R, Whalen E: Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther 2013;35:612-623.
[PubMed]
https://doi.org/10.1016/j.clinthera.2013.03.008
16.
McCarberg BH, Barkin RL: Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8:181-186.
[PubMed]
https://doi.org/10.1097/00045391-200105000-00006
17.
Mustafa M, Carson-Stevens A, Gillespie D, Edwards AG: Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2013;6:CD004253.
[PubMed]
https://doi.org/10.1002/14651858.CD004253.pub3
18.
Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O: Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012;8:CD008465.
[PubMed]
https://doi.org/10.1002/14651858.CD008465.pub2
19.
Schneider G, Voltz R, Gaertner J: Cancer pain management and bone metastases: an update for the clinician. Breast Care (Basel) 2012;7:113-120.
[PubMed]
https://doi.org/10.1159/000338579
20.
Kaasa S, Loge JH: Quality-of-life assessment in palliative care. Lancet Oncol 2002;3:175-182.
[PubMed]
https://doi.org/10.1016/S1470-2045(02)00682-4
21.
Young T, De Haes HC, Curran D, Fayers P, Brandberg Y; on behalf of the EORTC Quality of Life Group: Guidelines for Assessing Quality of Life in EORTC Clinical Trials. Brussels, EORTC, 1999.
22.
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
[PubMed]
https://doi.org/10.1016/S0304-3959(01)00349-9
23.
Farrar JT, Berlin JA, Strom BL: Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003;25: 406-411.
[PubMed]
https://doi.org/10.1016/S0885-3924(03)00162-3
24.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16: 139-144.
[PubMed]
25.
Schwarz R, Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37:1345-1351.
[PubMed]
https://doi.org/10.1016/S0959-8049(00)00447-0
26.
Kim SH, Son BH, Hwang SY, Han W, Yang JH, Lee S, Yun YH: Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 2008;35:644-655
[PubMed]
https://doi.org/10.1016/j.jpainsymman.2007.08.012
27.
Borneman T, Koczywas M, Sun VC, Piper BF, Uman G, Ferrell B: Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage 2010;39:486-501.
[PubMed]
https://doi.org/10.1016/j.jpainsymman.2009.08.007
28.
Deandrea S, Montanari M, Moja L, Apolone G: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19: 1985-1991.
[PubMed]
https://doi.org/10.1093/annonc/mdn419
29.
Potter VT, Wiseman CE, Dunn SM, Boyle FM: Patient barriers to optimal cancer pain control. Psychooncology 2003;12:153-160.
[PubMed]
https://doi.org/10.1002/pon.627
30.
Jacobsen R, Moldrup C, Christrup L, Sjogren P: Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci 2009;23:190-208.
[PubMed]
https://doi.org/10.1111/j.1471-6712.2008.00601.x
31.
Smith MY, DuHamel KN, Egert J, Winkel G: Impact of a brief intervention on patient communication and barriers to pain management: results from a randomized controlled trial. Patient Educ Couns 2010;81:79-86.
[PubMed]
https://doi.org/10.1016/j.pec.2009.11.021
32.
Wong P, Muanza T, Hijal T, Masse L, Pillay S, Chasen M, Lowensteyn I, Gold M, Grover S: Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study. Curr Oncol 2012;19:e129-135.
[PubMed]
https://doi.org/10.3747/co.19.905
© 2014 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.